All information on this website is intended strictly for educational and research purposes only.
The content on OpenPep — including peptide profiles, clinical trial summaries, dosing information, and reconstitution calculators — must not be used for:
OpenPep aggregates publicly available clinical trial data and research. We do not sell, distribute, or recommend any substances. All AI-generated summaries are interpretations of published research and may contain errors.
12,218 studies indexed across all peptides
Showing 10457 matching results
GM crops & food 17 (1) :2620886 · 2026-12-01
Scientists in South Korea wanted to find out if a genetically modified (GM) soybean plant — engineered to produce more omega-3 fatty acids — is safe and similar enough to regular soybeans to be considered "substantially equivalent." To do this, they ran field tests over three years at two different locations and used a powerful chemical analysis technique called non-targeted metabolomics, which scans for hundreds of different natural compounds in the soybean seeds at once. The results showed that where and when the soybeans were grown had a big impact on their chemical makeup — even more than whether the plant was genetically modified or not. Most of the chemical differences found in the GM soybeans fell within the natural range seen in regular, non-GM soybean varieties. The one consistent difference was a higher level of a compound called β-amyrin, which is a natural building block for certain plant chemicals called saponins. Researchers believe this change is a natural side effect of boosting omega-3 production, not a sign of danger. Overall, the study concludes that these omega-3-enriched GM soybeans are substantially equivalent to conventional soybeans, meaning they are chemically similar enough to be considered safe. The researchers also argue that non-targeted metabolomics is a useful tool to add to the standard safety testing process for GM crops, giving regulators a more complete picture of any chemical changes in the plant.
Journal of medical economics 29 (1) :1111-1129 · 2026-12-01
This study looked at whether a weight-loss drug called tirzepatide is worth the money compared to just diet and exercise for people who are overweight or obese in the UK. Researchers built a detailed computer model that simulates what happens to patients over a long period of time, including their risk of developing type 2 diabetes and a breathing condition called obstructive sleep apnea (OSA). The model used data from a large clinical trial program called SURMOUNT and included several improvements over older models. The computer model calculated costs and health benefits, measuring outcomes in quality-adjusted life years (QALYs), which combine how long someone lives with how good their quality of life is. The model found that tirzepatide at all tested doses was cost-effective under the UK health system's standard threshold of £20,000 per QALY gained. This means the drug provides enough health benefit to justify its cost compared to diet and exercise alone. The researchers also made technical improvements, like switching the model from an older programming language (VBA) to R, which made it run much faster and more reliably. While this is a modeling study rather than a direct patient trial, it offers useful guidance for health policymakers deciding whether to fund tirzepatide for weight management in the UK and potentially other countries.
2026-12-01
Journal of medical economics 29 (1) :698-711 · 2026-12-01
This study compared the cost of two diabetes medicines — tirzepatide and semaglutide — in the United Kingdom, looking at how much it costs to get one patient to reach important health goals like better blood sugar control and weight loss. Instead of just comparing drug prices, researchers calculated a "cost per success" — meaning how much money is spent for every patient who actually hits those targets. The data came from a large clinical trial called SURPASS-2, which included 1,845 patients. The results showed that tirzepatide was generally cheaper per successful patient than semaglutide, especially when the health goals were harder to reach (like losing 15% of body weight AND getting blood sugar under tight control). For example, for the strictest goal tested, tirzepatide saved between £5,650 and £9,462 per successful patient compared to semaglutide. Semaglutide only came out ahead on one of the six goals tested. This type of study is called a cost-to-target analysis, and it helps doctors and health systems decide which treatment gives the most value for money. While it offers useful information, it is based on calculations from an existing trial rather than a brand-new experiment, which means the findings depend heavily on the quality and design of that original study.
Journal of medical economics 29 (1) :242-248 · 2026-12-01
This study looked at two diabetes and heart disease medications — semaglutide (brand name Wegovy) and dulaglutide (brand name Trulicity) — to figure out how much it costs to prevent one bad health event, like a heart attack or stroke. Researchers used a math tool called "Number Needed to Treat" (NNT), which tells you how many patients need to take a drug to prevent one harmful event. The lower the NNT, the more effective the drug is. They also calculated the "Cost Per Event Avoided" (CPEA), which shows how much money it takes to prevent that one bad event. The key finding was that when researchers only looked at the main outcome from a clinical trial (like heart attack, stroke, or cardiovascular death), the drugs appeared less cost-effective than when they looked at a broader range of health outcomes — including kidney and metabolic problems. For semaglutide, the cost to prevent one event dropped from about $1.66 million (narrow measure) to just $190,000 (broad measure). For dulaglutide, it dropped from about $1.88 million to $608,000. This shows that how you measure a drug's benefit makes a huge difference in how valuable it seems. The researchers argue that judging a drug only by its primary trial endpoint gives an incomplete picture. When more health outcomes are included — especially ones affecting the heart, kidneys, and metabolism — these medications look much more valuable. The study encourages doctors, payers, and policymakers to use broader measures when deciding whether a treatment is worth its cost.
Systems biology in reproductive medicine 72 (1) :168-184 · 2026-12-01
About 10% of couples who struggle to get pregnant are told they have "unexplained infertility," meaning doctors can't find a clear reason why. This study looked for clues inside the fluid that surrounds eggs in the ovary, called follicular fluid. Researchers compared this fluid from 10 women with unexplained infertility to 10 women whose partners had fertility issues (used as a comparison group). They used a powerful chemical analysis tool to detect and measure thousands of tiny molecules in the fluid. The scientists found 12 molecules that were at different levels in the unexplained infertility group. Most of these molecules — including certain fats, vitamin D-related compounds, and other building blocks — were lower than normal. One molecule was higher than normal. They also found that even though all the women were taking vitamin D supplements, women with unexplained infertility still had lower vitamin D levels inside their follicles. This suggests something may be going wrong with how vitamin D is processed or delivered to the egg's environment. It's important to know that this was a very small, early-stage study with only 20 women total. The results are interesting and give researchers new leads to follow, but they are not strong enough yet to change how doctors treat infertility. Much larger studies are needed to confirm whether these molecular differences are truly connected to unexplained infertility or are just a coincidence.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 39 (1) :2667973 · 2026-12-01
Asia-Pacific journal of oncology nursing 13 :100943 · 2026-12-01
This study looked at the best ways to care for cancer patients who develop skin problems as a side effect of immunotherapy. These skin problems, called cutaneous immune-related adverse events (cirAEs), can happen when the immune system is activated by cancer treatments and starts to affect the skin. The researchers searched through a large number of medical databases and websites — both Chinese and English — to find the most reliable and up-to-date information on how nurses and doctors should handle these skin issues. After reviewing 24 high-quality articles including guidelines, expert opinions, and research reviews, the team came up with 25 recommendations covering five main areas: how to prevent skin problems, how to assess and grade their severity, what nursing care steps to take, how to educate patients, and how to follow up over time. Of these 25 recommendations, 17 were considered strong and 8 were considered weaker due to less supporting evidence. This type of study — called a systematic evidence review — is useful because it pulls together the best available knowledge into one place, making it easier for healthcare teams to follow consistent, proven steps when caring for patients with these skin side effects. While this study does not test a new treatment on patients directly, it gives nurses and clinicians a solid roadmap based on the current best evidence from two major medical literature traditions.
Asia-Pacific journal of oncology nursing 13 :100937 · 2026-12-01
This study looked at what it means for cancer patients to be "prepared for death." The researchers didn't run a clinical trial — instead, they reviewed 21 published research articles and used a special method called Rodgers' evolutionary concept analysis to break down and define the idea of death preparedness. Think of it like building a detailed dictionary definition backed by real research. The researchers found that being prepared for death involves five main parts: accepting that death will come, adjusting emotions, talking openly with others, sharing personal wishes, and making plans for end-of-life care. They also looked at what leads to death preparedness (like personal beliefs, family relationships, and social support) and what happens as a result (benefits for the patient, their family, and even society as a whole). This kind of study is important because it gives doctors and nurses a clearer picture of what death preparedness really means, which can help them have better conversations with patients and families. While it doesn't test a new treatment, it lays the groundwork for building tools and guidelines that can improve end-of-life care for people with cancer.
Renal failure 48 (1) :2620155 · 2026-12-01
Researchers wanted to know if a group of diabetes medications called GLP-1 receptor agonists (like semaglutide and liraglutide) could help protect the heart and kidneys in people with chronic kidney disease (CKD). To find out, they gathered and analyzed data from 9 different clinical trials that included over 21,700 patients. Most of these patients also had Type 2 diabetes. This type of study, called a meta-analysis, is powerful because it combines results from many studies to get a clearer picture of whether a treatment works. The results were encouraging. Patients who took GLP-1 receptor agonists were about 16% less likely to experience serious kidney problems, 16% less likely to have a major heart attack or stroke, and 17% less likely to die from any cause compared to those who didn't take these medications. The drugs also lowered a marker in the urine called albuminuria, which is a sign of kidney damage. These benefits were mostly seen in patients who had both CKD and Type 2 diabetes. However, the medications came with some notable side effects, mainly involving the stomach and digestive system. Patients on GLP-1 receptor agonists were about 4 times more likely to experience nausea, nearly 4 times more likely to have indigestion, and about 3 times more likely to experience vomiting or diarrhea. While these side effects can be uncomfortable, the overall findings suggest that these medications offer strong protective benefits for the heart and kidneys in people with CKD and Type 2 diabetes.
2026-11-15
Researchers are planning a clinical trial to test whether tirzepatide — a drug currently approved for diabetes and weight loss (known by the brand name Zepbound or Mounjaro) — might also help people quit or cut back on marijuana use. The study will involve 100 people and will be conducted in a "double-blind, placebo-controlled" way, meaning half the participants will get the real drug and half will get a sugar pill, and neither the patients nor the doctors running the study will know who is getting which. The drug will start at a low dose of 2.5 mg and may increase over time depending on how well participants tolerate it. The trial is still in the planning stage and hasn't started enrolling patients yet. It is expected to begin in November 2026 and wrap up by November 2028. Scientists will track how many days per week participants go without using cannabis, as well as the highest dose of the medication that people can safely handle. This is considered a "Phase 2" trial, which means it is an early-stage test focused on safety and initial effectiveness before larger studies are done. It's important to note that this study has not yet produced any results, and the findings have not been reviewed by other scientists yet. However, it has some encouraging features: it is not funded by the pharmaceutical industry, and it uses a strong research design with randomization and blinding. Cannabis Use Disorder is a condition where a person feels unable to control their marijuana use even when it causes problems in their life, and currently there are no FDA-approved medications to treat it — making this research potentially very meaningful.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 359 :127966 · 2026-10-15
Gastrodia elata (GE) is a plant used in both cooking and traditional medicine across Asia. In this study, researchers looked at GE samples from 9 different growing regions in China to see if the place where it grows affects its chemical makeup. They used a special light-based scanner called FT-NIR and a detailed chemical analysis method called UPLC-MS/MS to compare the samples. The researchers found clear differences between GE grown in Yunnan compared to Hubei and Guizhou provinces. They also noticed that the color and appearance of the plant were linked to its internal chemistry — plants with certain color values tended to have more or fewer specific health-related compounds like flavonoids and phenolic acids. Out of 810 polyphenol compounds identified, 257 showed meaningful differences between growing regions. The study also found that temperature and humidity in a region play a big role in how the plant builds up its beneficial compounds. This kind of research helps farmers, manufacturers, and buyers understand that where GE is grown really matters for its quality and potential health benefits. However, since this was a lab-based chemical analysis and not a clinical trial involving human participants, it does not directly tell us how these differences affect people's health.
2026-10-01
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 357 :127790 · 2026-09-05
This study looked at a traditional Chinese herb called Angelica dahurica, which is used both as medicine and food. The herb's quality depends a lot on where it is grown, but dried slices from different regions look almost identical, making it hard to tell them apart. Researchers used a technology called mid-infrared spectroscopy — which shines light on a sample and reads how it absorbs different wavelengths — combined with computer-based machine learning to figure out where the herb came from and check its quality. The team tested several different computer models to see which ones were best at identifying the herb's origin and predicting important quality measures like moisture content, a chemical called coumarin, and ash content. One model called PLS-DA was especially good at identifying the geographical origin, getting it right about 99% of the time. Moisture content was also predicted very accurately, while coumarin prediction was decent. Ash content was harder to predict reliably. Overall, this research offers a fast, non-destructive way to check where Angelica dahurica comes from and whether it meets quality standards. This is important for protecting consumers and ensuring the authenticity of traditional herbal medicines. However, since the study did not clearly report how many samples were tested, it is hard to know how well these results would hold up on a much larger scale.
Bioactive materials 63 :778-794 · 2026-09-01
Radiation therapy is a common cancer treatment, but it often causes painful skin injuries that are hard to heal. Researchers developed a special gel called HCG@CDs that can be injected into damaged skin. This gel is made from natural, body-friendly materials and contains tiny carbon particles that act like a natural antioxidant enzyme. The gel is designed to respond to the wound's environment, releasing its healing ingredients at the right time and place. The gel works in two stages. First, when it senses the acidic environment of a fresh wound, it quickly releases carbon dots that mop up harmful molecules called reactive oxygen species (ROS), which cause much of the early damage. Later, the gel slowly releases a copper-based compound called GHK-Cu that helps reduce inflammation, encourages cells to move in and multiply, and promotes the formation of collagen, which is the building block of healthy skin. Tests were done in lab dishes and in living animals, and both showed that this gel sped up healing of radiation-damaged skin. While the results are promising, this research is still in early stages — no human trials have been reported yet. More testing in people will be needed before this treatment could become widely available.
2026-08-27
This clinical trial is testing a medicine called CagriSema in people who have Type 2 diabetes. CagriSema is a combination drug that brings together two medicines — cagrilintide and semaglutide — into one treatment. The study wants to find out if two different versions (or "presentations") of the drug work equally well. About 400 people will be randomly placed into groups, and neither the patients nor their doctors will know which version they are receiving. The trial is expected to start in August 2026 and wrap up by October 2027. The main thing researchers are measuring is how much the drug lowers HbA1c — a blood test that shows average blood sugar levels over the past 2-3 months — after 28 weeks of treatment. They are also tracking how the drug moves through the body, how often side effects happen, and whether any participants experience dangerously low blood sugar (hypoglycemia). A lower HbA1c is a sign that blood sugar is better controlled, which is the goal for people with Type 2 diabetes. It is important to note that this study has not started yet and has no results to share. The trial is funded by the drug's manufacturer, which can sometimes influence how a study is designed or reported. It also has not yet been peer reviewed, meaning independent scientists have not checked the research plan. Readers should keep these points in mind when thinking about how much weight to give this study's future findings.
2026-08-15
This clinical trial is testing a new oral drug called NA-931 in people who are overweight or obese. The study will look at whether NA-931 works on its own, and also whether it works even better when combined with tirzepatide — a well-known injectable weight-loss medication (the active ingredient in Mounjaro and Zepbound). The trial has not started yet and is expected to begin in August 2026, with results expected by December 2027. The study is carefully designed to be fair and trustworthy. It is "double-blind," meaning neither the patients nor the doctors know who is getting the real drug versus a placebo (a dummy pill). There are 9 different treatment groups testing different doses of NA-931 (0, 60, or 150 mg by mouth) combined with different doses of tirzepatide (none, 2.5 mg, or 5 mg/10 mg by injection). A total of 224 adults will take part across multiple hospitals or clinics. The study lasts about 48 weeks of active treatment, followed by additional follow-up periods. While the study design is solid for an early-phase trial, there are some important limitations to keep in mind. The sample size of 224 people is relatively small, which is typical for a Phase 2 trial but means the results may not apply to everyone. The study has not yet been peer-reviewed, and it is funded by industry (the company that makes NA-931), which can sometimes influence how results are reported. No results are available yet, so we do not know if the drug actually works.
Journal of affective disorders 407 :121802 · 2026-08-15
This study looked at whether GLP-1 receptor agonist drugs — like semaglutide (Ozempic/Wegovy), liraglutide, and tirzepatide — are linked to depression or suicidal thoughts in people with type 2 diabetes. Researchers searched a massive World Health Organization database of drug side effect reports from 2010 to 2024, comparing millions of reports for GLP-1 drugs versus other diabetes medications. They used special math tools to figure out whether these drugs were reported more often alongside mood problems than other diabetes treatments. The results showed that semaglutide and liraglutide had notably higher rates of reported depressed mood and suicidal thoughts compared to other diabetes drugs, while tirzepatide showed a smaller signal. However, an important detail stood out: people taking these GLP-1 drugs were also much more likely to already be on antidepressants or have a history of depression. This suggests that patients who are already emotionally vulnerable may be more likely to report these mood problems — not necessarily because the drug itself caused them. The researchers concluded that GLP-1 drugs are still safe and useful for treating diabetes, but doctors should keep a closer eye on patients who already have mental health challenges, especially in the first few months of starting treatment. No increased signal was found for actual suicide attempts or completed suicide, and the overall number of mood-related reports was low compared to the total number of drug reports.
Journal of pharmaceutical and biomedical analysis 276 :117470 · 2026-08-15
This study looked at a traditional Chinese herbal medicine ingredient called Citri Reticulatae Pericarpium (CRP), which is basically dried citrus peel. There are different varieties of CRP, and it can be hard to tell them apart just by looking at them. Scientists used a powerful chemical analysis tool called UHPLC-QTOF-MS, along with computer-based machine learning, to find chemical "fingerprints" that could reliably identify which variety of CRP a sample came from. The research team analyzed hundreds of chemical compounds found in four different CRP varieties and used advanced statistics to narrow down the most important differences. They found 46 key chemical markers that could tell the varieties apart, and then built 9 different machine learning models using those markers. All of the models performed very well, correctly identifying CRP varieties over 94% of the time in testing, and achieving a perfect 100% accuracy on outside samples used to check the results. One especially useful finding was that a compound called nobiletin could specifically separate the officially approved (pharmacopoeia) varieties of CRP from non-approved ones. This matters a lot for quality control in herbal medicine markets, where mislabeling or substitution can be a problem. The study shows that combining advanced chemistry tools with machine learning is a promising way to ensure herbal medicine products are authentic and meet quality standards.
Journal of affective disorders 407 :121802 · 2026-08-15
This study looked at whether GLP-1 receptor agonist drugs — like semaglutide (Ozempic/Wegovy), liraglutide, and tirzepatide — are linked to depression or suicidal thoughts in people with type 2 diabetes. Researchers searched a massive World Health Organization database of drug side effect reports from 2010 to 2024, comparing millions of reports for GLP-1 drugs versus other diabetes medications. They used special math tools to figure out whether these drugs were reported more often alongside mood problems than other diabetes treatments. The results showed that semaglutide and liraglutide had notably higher rates of reported depressed mood and suicidal thoughts compared to other diabetes drugs, while tirzepatide showed a smaller signal. However, an important detail stood out: people taking these GLP-1 drugs were also much more likely to already be on antidepressants or have a history of depression. This suggests that patients who are already emotionally vulnerable may be more likely to report these mood problems — not necessarily because the drug itself caused them. The researchers concluded that GLP-1 drugs are still safe and useful for treating diabetes, but doctors should keep a closer eye on patients who already have mental health challenges, especially in the first few months of starting treatment. No increased signal was found for actual suicide attempts or completed suicide, and the overall number of mood-related reports was low compared to the total number of drug reports.